Also known as examorelin, ep23905, hexarelin acetate · Wikipedia
Hexarelin (examorelin) is a synthetic hexapeptide growth hormone-releasing peptide (GHRP) developed in the 1990s and one of the most potent GHRPs for acute GH release. It is a full agonist at the ghrelin receptor (GHS-R1a) on pituitary somatotrophs and uniquely also binds the cardiac CD36 scavenger receptor, where it has shown cardioprotective effects in animal and small human studies. Phase II trials in cardiac and GH-deficiency indications were completed but development was not advanced and hexarelin is not FDA-approved. It is used in the research-chemical channel for GH release and recovery.
—
best
price
—
per
mg
—
vendors
tracked
Phase II
stage
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
Hexarelin (examorelin) is a synthetic hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) and one of the most potent growth-hormone-releasing peptides characterized. It is a full agonist at the ghrelin receptor (GHS-R1a) on pituitary somatotrophs and hypothalamic neurons, driving acute pulsatile GH release in humans in a dose-dependent manner (Imbimbo et al.
Pharmacokinetic properties
Half-life
~55-70 minutes intravenous; ~70 min subcutaneous
Routes
subcutaneous · intranasal · intravenous
Bioavailability
Active orally and intranasally as well as parenterally, though SC/IV most studied. Pronounced receptor desensitization develops within ~4 weeks of continuous dosing.
Amino-acid sequence
His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2
Use & research dosing
Self-experimentation protocols circulating in the research-chemical channel commonly use 100 mcg subcutaneously 1-2 times daily in short cycles of 4-8 weeks to limit receptor desensitization. Published clinical research has used 1-2 mcg/kg IV or SC bolus for acute GH-release studies and 1.5-2.0 mcg/kg twice daily SC in chronic Phase 2 work. Intranasal and oral routes have been studied but are less practical. Not FDA-approved; research framing only.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
Notable for dual action at GHS-R1a and CD36 - the latter underlies its distinct (and intriguing) cardiac effects, which prompted Phase 2 cardiac trials that did not advance to registration. Largely displaced by ipamorelin in general GH-secretagogue research because of the cortisol and prolactin elevation profile. Phase II/III completed but never approved by FDA, EMA, or UK MHRA. The strong acute GH response is reproducible; rapid desensitization limits chronic utility.
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Research foundation
Facts verified
2026-05-25
Confidence
low
What this means
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.